Procalcitonin-based indication of bacterial infection identifies high risk acute heart failure patients

International Journal of Cardiology

Volumn 204, Issue , 2016, Pages 164-171

  Demissei, Biniyam G ^a   Cleland, John G ^b   O'Connor, Christopher M ^c   Metra, Marco ^d   Ponikowski, Piotr ^e   Teerlink, John R ^f   Davison, Beth ^g   Givertz, Michael M ^h   Bloomfield, Daniel M ⁱ   Dittrich, Howard ^j   Van Veldhuisen, Dirk J ^a   Hillege, Hans L ^a   Voors, Adriaan A ^a   Cotter, Gad ^g  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF BRESCIA   (Italy)

^e WROCLAW MEDICAL UNIVERSITY   (Poland)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g Momentum Research Inc   (United States)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

ⁱ MERCK RESEARCH LABORATORIES   (United States)

^j UNIVERSITY OF IOWA   (United States)

more..

Author keywords

Acute heart failure; Bacterial infection; Procalcitonin; Prognosis

Indexed keywords

ALBUMIN; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; HEMOGLOBIN; NITROGEN; PROCALCITONIN; UREA; BIOLOGICAL MARKER; CALCITONIN; PROTEIN PRECURSOR;

ACUTE HEART FAILURE; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BACTERIAL INFECTION; CLINICAL EVALUATION; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; TREATMENT FAILURE; UREA NITROGEN BLOOD LEVEL; ACUTE DISEASE; BACTERIAL INFECTIONS; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HEART FAILURE; HOSPITAL DISCHARGE; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TRENDS; VERY ELDERLY;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; BACTERIAL INFECTIONS; BIOMARKERS; CALCITONIN; DOUBLE-BLIND METHOD; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MORTALITY; PATIENT DISCHARGE; PROTEIN PRECURSORS; RISK FACTORS;

EID: 84955313476     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.11.141     Document Type: Article

References (32)

1. G.C. Fonarow, W.T. Abraham, and N.M. Albert OPTIMIZE-HF Investigators and Hospitals Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF Arch. Intern. Med. 168 2008 847 854
2. D. Alon, G.Y. Stein, R. Korenfeld, and S. Fuchs Predictors and outcomes of infection-related hospital admissions of heart failure patients PLoS One 8 2013 e72476
3. A. Maisel, S.X. Neath, J. Landsberg, and et al. Use of procalcitonin for the diagnosis of pneumonia in patients presenting with a chief complaint of dyspnoea: results from the BACH (biomarkers in acute heart failure) trial Eur. J. Heart Fail. 14 2012 278 286
4. P. Schuetz, A. Kutz, and E. Grolimund ProHOSP Study Group Excluding infection through procalcitonin testing improves outcomes of congestive heart failure patients presenting with acute respiratory symptoms: results from the randomized ProHOSP trial Int. J. Cardiol. 175 2014 464 472
5. D. Epstein, D. Raveh, Y. Schlesinger, B. Rudensky, N.P. Gottehrer, and A.M. Yinnon Adult patients with occult bacteremia discharged from the emergency department: epidemiological and clinical characteristics Clin. Infect. Dis. 32 2001 559 565
6. M. Gonzalez-Del Vecchio, E. Bunsow, C. Sanchez-Carrillo, E. Garcia Leoni, M. Rodriguez-Creixems, and E. Bouza Occult bloodstream infections in adults: a "benign" entity Am. J. Emerg. Med. 32 2014 966 971
7. T.A. Seigel, M.N. Cocchi, J. Salciccioli, and et al. Inadequacy of temperature and white blood cell count in predicting bacteremia in patients with suspected infection J. Emerg. Med. 42 2012 254 259
8. J. Almirall, I. Bolibar, and P. Toran Community-Acquired Pneumonia Maresme Study Group Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia Chest 125 2004 1335 1342
9. J.P. Haran, F.L. Beaudoin, S. Suner, and S. Lu C-reactive protein as predictor of bacterial infection among patients with an influenza-like illness Am. J. Emerg. Med. 31 2013 137 144
10. P. Povoa, L. Coelho, E. Almeida, and et al. C-reactive protein as a marker of infection in critically ill patients Clin. Microbiol. Infect. 11 2005 101 108
11. S.A. Flanders, J. Stein, G. Shochat, and et al. Performance of a bedside C-reactive protein test in the diagnosis of community-acquired pneumonia in adults with acute cough Am. J. Med. 116 2004 529 535
12. B. Clyne, and J.S. Olshaker The C-reactive protein J. Emerg. Med. 17 1999 1019 1025
13. A.P. Kalogeropoulos, W.H. Tang, A. Hsu, and et al. High-sensitivity C-reactive protein in acute heart failure: insights from the ASCEND-HF trial J. Card. Fail. 20 2014 319 326
14. A.S. Maisel, and R. Choudhary Biomarkers in acute heart failure - state of the art Nat. Rev. Cardiol. 9 2012 478 490
15. L. Simon, F. Gauvin, D.K. Amre, P. Saint-Louis, and J. Lacroix Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis Clin. Infect. Dis. 39 2004 206 217
16. A. Holm, S.S. Pedersen, J. Nexoe, and et al. Procalcitonin versus C-reactive protein for predicting pneumonia in adults with lower respiratory tract infection in primary care Br. J. Gen. Pract. 57 2007 555 560
17. B. Muller, S. Harbarth, D. Stolz, and et al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia BMC Infect. Dis. 7 2007 10
18. W. Wang, X. Zhang, N. Ge, and et al. Procalcitonin testing for diagnosis and short-term prognosis in bacterial infection complicated by congestive heart failure: a multicenter analysis of 4,698 cases Crit. Care 18 2014 R4
19. R. Aabenhus, J.U. Jensen, K.J. Jorgensen, A. Hrobjartsson, and L. Bjerrum Biomarkers as point-of-care tests to guide prescription of antibiotics in patients with acute respiratory infections in primary care Cochrane Database Syst. Rev. 11 2014 CD010130
20. P. Schuetz, W. Albrich, and B. Mueller Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future BMC Med. 9 2011 (107-7015-9-107)
21. B.D. Weatherley, G. Cotter, and H.C. Dittrich PROTECT Steering Committee, Investigators, and Coordinators Design and rationale of the PROTECT study: a placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function J. Card. Fail. 16 2010 25 35
22. B.M. Massie, C.M. O'Connor, and M. Metra PROTECT Investigators and Committees Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure N. Engl. J. Med. 363 2010 1419 1428
23. P. Hausfater, S. Garric, S.B. Ayed, M. Rosenheim, M. Bernard, and B. Riou Usefulness of procalcitonin as a marker of systemic infection in emergency department patients: a prospective study Clin. Infect. Dis. 34 2002 895 901
24. G.A. Alba, Q.A. Truong, and H.K. Gaggin Global Research on Acute Conditions Team (GREAT) Network Diagnostic and prognostic utility of procalcitonin in patients presenting to the Emergency Department with dyspnea Am. J. Med. 2015, Jul 10 10.1016/j.amjmed.2015.06.037
25. C.M. O'Connor, R.J. Mentz, G. Cotter, and et al. The PROTECT in-hospital risk model: 7-day outcome in patients hospitalized with acute heart failure and renal dysfunction Eur. J. Heart Fail. 14 2012 605 612
26. J.G. Cleland, K. Chiswell, J.R. Teerlink, and et al. Predictors of postdischarge outcomes from information acquired shortly after admission for acute heart failure: a report from the placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function (PROTECT) study Circ. Heart Fail. 7 2014 76 87
27. S. Kruger, S. Ewig, and J. Papassotiriou CAPNETZ Study Group Inflammatory parameters predict etiologic patterns but do not allow for individual prediction of etiology in patients with CAP: results from the German competence network CAPNETZ Respir. Res. 10 2009 (65-9921-10-65)
28. C. Alvarez, and A. Ramos Lipids, lipoproteins, and apoproteins in serum during infection Clin. Chem. 32 1986 142 145
29. P. Schuetz, M. Christ-Crain, and R. Thomann ProHOSP Study Group Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial JAMA 302 2009 1059 1066
30. A. Mollar, M.P. Villanueva, A. Carratala, E. Nunez, J. Sanchis, and J. Nunez Determinants of procalcitonin concentration in acute heart failure Int. J. Cardiol. 177 2014 532 534
31. N.S. Lee, and L.B. Daniels Personalized CHF treatment: PCT to guide therapy in heart failure patients Int. J. Cardiol. 176 2014 307 308
32. M.P. Villanueva, A. Mollar, P. Palau, and et al. Procalcitonin and long-term prognosis after an admission for acute heart failure Eur. J. Intern. Med. 26 2015 42 48